Presentations on CLEC-1, a new myeloid checkpoint inhibitor target
In cancer immunotherapy
Nantes, France – May 11, 2022, 6 p.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) has been invited to present the progress of its immuno-oncology research and development programs at two international congresses to be held in May and June. The large presence of OSE Immunotherapeutics at events dedicated to scientific research on cancer confirms its expertise in the very attractive field of myeloid cells and macrophages, identified as being factors of poor prognosis in oncology and in escape mechanisms. current cancer immunotherapies.